Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS)
NCT ID: NCT02325869
Last Updated: 2015-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2015-07-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Intra-Drug Eluting Stent (DES) Restenosis Study
NCT00323895
Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4
NCT01632371
Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment
NCT03899818
Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent for de Novo Diffuse Disease Treatment
NCT03939468
Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice
NCT02853994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In some cases of CAD the blood vessel is chronically totally blocked (total occlusion), stopping blood flow through the blocked blood vessel. In these cases a minimally invasive treatment or a surgery may be needed. "Minimally invasive procedures" consist of angioplasty or stent placement. The procedure is performed under local anesthetic with the patient lying on their back.
Angioplasty is a routine, well known, non-surgical procedure that is performed by making a small incision of the skin in the groin through which a catheter (narrow tube) and a guidewire (a thin metal wire) are inserted to reach the blocked artery. After reaching the blocked artery and crossing the blockage with a guidewire, a tiny balloon is inflated inside the artery to open the blockage. During the course of this procedure small pieces of the material that is causing the blockage may break off and be carried by the blood stream to other parts of the body where they may lodge and cause damage by blocking the blood flow . The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bell Balloon Catheter
The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
Bell Balloon Catheter
An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bell Balloon Catheter
An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject is ≥18 years of age.
2. Subject with acute coronary syndrome (STEMI or NSTEMI).
3. Candidate for percutaneous coronary intervention (PCI) in native coronary artery.
4. Anticipated patient life expectancy of at least 1 year since enrollment.
5. Subject is male or a non-pregnant female.
6. Subject has provided written informed consent.
7. Subject is able and willing to adhere to the required follow-up visits and testing.
Angiographic Criteria
1. Lesions amendable to PCI.
2. Angiographically thrombotic-appearing lesion that amenable to PCI.
3. Lesion(s) is located within the native vessel and has ≥ 50% but \<100% stenosis.
4. The target lesion should be at least 10mm proximal to the proximal edge of a stented lesion.
5. Only a single lesion will be treated by the investigational device.
6. Vessel has thrombolysis in myocardial infarction (TIMI) grade 1 or higher flow before the use of the investigational device.
7. Reference vessel diameter, where the Bell balloon is to be placed, is 3-4mm in diameter by angiographic visual estimation.
Exclusion Criteria
1. Women except those whose menstrual periods have not occurred for more than one year after menopause or those who have had sterilization surgery (tubal ligation) or hysterectomy
2. Known contraindication to the use of heparin or bivalirum (Angiomax).
3. Known contraindication to the use of dual anti-platelet therapy
4. Known hypersensitivity to contrast media which cannot be adequately pretreated.
5. Subject has renal insufficiency, defined as baseline creatinine level ≥ 2.0 mg/dl.
6. Subject has a known history of neutropenia (WBC \<3,000/mm3) or significant anemia.
7. Subjects has a known history of coagulopathy or thrombophilia \[prothrombin International Normalized Ratio (INR)\>1.5, Platelet count\<80,000/ μL\], that has not resolved or has required treatment in the past 6 months.
8. Major bleeding within 6 months of index procedure.
9. A planned invasive surgical procedure within 30 days.
10. Undergone cardiac surgery within the past 30 days or has a planned surgical procedure within 30 days from study procedure
11. Left ventricular ejection fraction \< 25%
12. The patient is in cardiogenic shock or hemodynamic unstable
13. Cerebrovascular Accident (CVA) or TIA within the past 6 months.
14. Exclusions that preclude placement of the bell balloon per the Instruction for Use
15. Subject not capable of understanding and signing the Informed Consent form.
Angiographic Criteria
1. Anatomical exclusions that preclude placement of the bell balloon per the Instruction for Use.
2. Target lesion inside or within 10mm of a prior stent
3. Target lesion distal to a prior placed stent
4. Severe calcification at the lesion site or proximal to it.
5. Aorto-ostial lesions
6. Bifurcation lesions (side branch diameter ≥ 2.0mm)
7. Severe coronary artery tortuosity (Angulation \>450)
8. Target lesion is totally occluded, or Thrombolysis in Acute MI (TIMI flow 0) despite pre-dilatation with small caliber balloon
9. Coronary artery spasm in the absence of a significant stenosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Angioslide Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giora Weisz, Prof. M.D
Role: PRINCIPAL_INVESTIGATOR
Chairman, Department of Cardiology. Shaare Zedek Medical Center, Jerusalem Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shaare Zedek Medical Center
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-0013.CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.